目的 探討心欣舒膠囊聯(lián)合環(huán)磷腺苷葡胺治療病毒性心肌炎的臨床療效。方法 選取2015年3月-2016年3月延安大學(xué)附屬醫(yī)院收治的病毒性心肌炎患者76例，隨機(jī)分為對照組和治療組，每組各38例。對照組靜脈滴注注射用環(huán)磷腺苷葡胺，180 mg加入到5%葡萄糖溶液250 mL，1次/d。治療組在對照組基礎(chǔ)上口服心欣舒膠囊，5粒/次，3次/d。兩組患者均治療30 d。觀察兩組的臨床療效，比較血清心肌酶譜和血清學(xué)指標(biāo)的變化。結(jié)果 治療后，對照組和治療組的總有效率分別為78.95%、94.74%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者CK-MB、CPK、LDH和AST均明顯降低，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的降低程度明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者TNF-α和IL-6水平明顯降低，而SOD水平明顯升高，同組治療前后差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 心欣舒膠囊聯(lián)合環(huán)磷腺苷葡胺治療病毒性心肌炎具有較好的臨床療效，可明顯減輕心肌細(xì)胞損傷，降低炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of the treatment of Xinxinshu Capsules combined with meglumine adenosine cyclophosphate in treatment of viral myocarditis. Methods Patients (76 cases) with viral myocarditis in Yan'an University Affiliated Hospital from March 2015 to March 2016 were randomly divided into the control and treatment groups, and each group had 38 cases. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate for injection, 180 mg added into glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Xinxinshu Capsules on the basis of the control group, 5 grains/time, three times daily. After treatment, the clinical efficacies were evaluated, and the changes of serum myocardial enzyme spectrum and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.95% and 94.74%, respectively, and there was difference between two groups (P<0.05). After treatment, CK-MB, CPK, LDH, and AST in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-α and IL-6 in two groups were significantly decreased, but the levels of SOD in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xinxinshu Capsules combined with meglumine adenosine cyclophosphate has clinical curative effect in treatment of viral myocarditis, and can obviously reduce myocardial cell injury and inflammatory reaction, which has a certain clinical application value.